Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | P4HB | P07237 | 15/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795707 | 0.91 | PDCD1 (0.49) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL9101368 | 0.82 | TBXAS1 (0.49) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL9514413 | 0.82 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL9514417 | 0.82 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL5970556 | 0.82 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL5970550 | 0.82 | PDCD1 (0.57) | PDCD1CD274P4HBFBP1MAOA | |
| SCHEMBL712358 | 0.79 | FBP1 (0.48) | PDCD1CD274P4HBFBP1 | |
| SCHEMBL921088 | 0.79 | FBP1 (0.48) | PDCD1CD274P4HBFBP1 | |
| SCHEMBL712359 | 0.79 | FBP1 (0.48) | PDCD1CD274P4HBFBP1 | |
| SCHEMBL6166104 | 0.78 | PDCD1 (0.60) | PDCD1CD274P4HBFBP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | PDCD1 3406/4885CD274 4342/4885P4HB 808/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | PDCD1 3414/4885CD274 4296/4885P4HB 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.